Abrocitinib Summary of Clinical Safety (Atopic Dermatitis)
Proportion and Incidence Rates for Treatment-Emergent Herpes Simplex (CMQ) - Short-Term Safety Pool

	Placebo	Abrocitinib 100mg QD	Abrocitinib 200mg QD	All Abrocitinib
N	454	719	698	1417
Number of Subjects with Event, n (%[1])	0	0	0	0
Total Drug Exposure (PY)	113.94	184.94	182.44	367.38
Incidence Rates (95% CI)[1]	0.00 (0.00, 3.24)	0.00 (0.00, 1.99)	0.00 (0.00, 2.02)	0.00 (0.00, 1.00)

Includes Studies: B7451006, B7451012, B7451013, B7451029, B7451036
Includes data up to the end of risk period (the smaller of [last dose date, death date] for B7451012/13/36 subjects who enrolled into the LTE study; or the smaller of [last dose date prior to Week 16 dose date/visit date, death date] for B7451029 subjects with available Week 16 dose date/visit date; otherwise, the smaller of [last dose date + 28 days, death date]).
PY (Patient-Year): Total follow up time calculated up to the day of the first event for subjects with events, and up to the end of risk period for subjects without events.
n: Number of subjects with the event. Incidence Rates: Number of subjects with events per 100 patient-years.
Confidence intervals (CI) were calculated for incidence rates based on the assumption that the actual count of cases arises from a Poisson distribution for treatment groups with zero event; otherwise they were based on gamma distribution weighted by study-size.
[1]Study-size adjusted results.